COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Watch the WCG COVID-19 Webinar Series On-Demand
Join thousands of your peers in watching WCG’s webinar series, where clinical trial and public health experts provide the insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from June 11, 2021
Recent Insights from WCG
The map below displays WCG locations. The same locations are listed below the map.
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
FDA Allows Stalled Emergent Plant to Resume Producing J&J Vaccine
The FDA has given Emergent BioSolutions’ Bayview, Md., facility the green light to restart manufacturing Johnson & Johnson’s (J&J) COVID-19 vaccine — months after new production was put on hold following the discovery of numerous quality issues and cross-contamination with AstraZeneca vaccine doses.
Third Pfizer Vaccine Dose Ratchets Up Protection Against Delta Variant
The drugmaker projected that a third dose could yield a 100-fold increase in neutralization of the Delta variant when compared against the two-dose regimen.
EU Orders Supplies of GSK’s Experimental COVID-19 Drug
The European Medicines Agency is evaluating sotrovimab under a rolling review.
Shionogi Begins Human Trials of First Once-A-Day Pill for COVID-19 Patients
No adverse events were observed after the initial dose administered last week, the company said.
WHO Finds Guillain-Barré Syndrome Cases Rare in Adenovirus-Based COVID-19 Vaccines
The FDA and EMA have listed the condition as a very rare possible side effect of inoculations with the Johnson & Johnson COVID-19 vaccine.
CDC Panel Endorses J&J Vaccine Despite Guillain-Barré Syndrome Risk
A Centers for Disease Control and Prevention (CDC) expert panel has recommended continued use of the single-dose Johnson & Johnson (J&J) COVID-19 vaccine despite reports of Guillain-Barré syndrome (GBS), a neurological illness, in a small number of inoculated individuals.
Single AstraZeneca Vaccine Dose Highly Effective Against Delta Variant, Study Says
The real-world analysis comprised nearly 70,000 individuals who contracted the SARS-CoV-2 virus from December 2020 to May 2021 in the province of Ontario.
UK Researchers Endorse Eight-Week Separation of Pfizer Vaccine Doses
Given concerns about the rapidly spreading Delta variant, an eight-week window was deemed preferable by the researchers from Oxford and Newcastle universities.
Pfizer-BioNTech Vaccine to be Partly Produced in South Africa
Biovac currently manufactures and distributes Pfizer’s Prevenar 13 pneumococcal vaccine.
EMA Begins Rolling Review of Sanofi’s COVID-19 Vaccine
Early trial results have shown the vaccine induces protective antibodies against the coronavirus.
Woodcock, Other FDA Officials Offer Regulatory Insights at Annual Industry Meeting
The FDA has resumed routine domestic inspections this month after hitting the pause button for all but mission-critical inspections in March 2020, said Acting Commissioner Janet Woodcock yesterday on day-one of the FDA’s five-day Regulatory Education for Industry Annual Conference.
EMA Evaluates the Use of Kineret in Adult COVID-19 Patients
The EMA’s human medicines committee is assessing data from two clinical trials and is expected to reach a decision by October, unless more information is required.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.